Physiological Effects of Grape Seed Extract in Diastolic Heart Failure



Status:Active, not recruiting
Conditions:High Blood Pressure (Hypertension), Other Indications, Cardiology, Psychiatric
Therapuetic Areas:Cardiology / Vascular Diseases, Psychiatry / Psychology, Other
Healthy:No
Age Range:50 - Any
Updated:5/12/2016
Start Date:August 2010
End Date:December 2017

Use our guide to learn which trials are right for you!

GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure

Diastolic heart failure (also known as "heart failure with normal ejection fraction" or
"heart failure with preserved ejection fraction") occurs even though the heart muscle's
pumping function is normal. In many cases diastolic heart failure is related to stiffening
of the heart and blood vessels in people who have high blood pressure. Current guidelines
suggest that patients should limit the salt content of their diet, as too much salty food
can cause fluid retention and other problems in diastolic heart failure. Studies in animals
with diastolic heart failure suggest that antioxidant chemicals found in grapes can block
some of the harmful effects of salty diets. Because it is often difficult for patients with
diastolic heart failure to maintain a low salt diet, the investigators are researching the
effects of the antioxidant properties of grape seed extract, a natural supplement made from
grape seeds. The investigators hypothesize that supplementing the diet with grape seed
extract (GSE) can decrease the levels of harmful chemicals and improve heart and blood
vessel function in patients with diastolic heart failure and a history of high blood
pressure.

The University of Michigan research group plans to enroll 25 patients with a history of high
blood pressure and diastolic heart failure in a research study. The study will assess the
effects of GSE on hormones and other chemicals that can cause heart and blood vessel damage.
The investigators will also study the effects of GSE on the ability of the blood vessels and
heart muscles to relax at the proper time and speed. Finally, the investigators will observe
how GSE affects participants' overall ability to exercise, quality of life, and blood
pressure control. Study participants will be randomly assigned to take either GSE or placebo
(looks like but does not contain GSE) capsules twice a day for six weeks. After a two-week
break, all subjects will cross over to the opposite group of capsules for an additional
six-week period. At the start of the study and at the end of each six-week time period study
participants will have non-invasive heart and blood vessel testing, blood work and urine
tests, and blood pressure monitoring.


Inclusion Criteria:

Inclusion:

- Signs and symptoms of heart failure

- Left ventricular ejection fraction ≥ 50% (contrast ventriculography,
echocardiography, nuclear scintigraphy, MRI or CT imaging)

- Diastolic dysfunction on previous echocardiogram/catheterization, or indeterminate
diastolic function with supporting evidence of heart failure (HF) (as per European
Society of Cardiology guidelines)

- History of systemic hypertension

- Age ≥ 50 years

- Willing to adhere to prescribed course of supplementation

- Informed consent

Exclusion Criteria:

- Daily intake of antioxidant supplements or vitamins beyond that provided in a
standard daily multivitamin (e.g. high-dose vitamin E or vitamin C)

- NYHA Class IV heart failure symptoms (except during previous hospitalization)

- Hospitalization for decompensated heart failure within past one month

- Severely uncontrolled hypertension (SBP ≥ 180 and.or DBP ≥ 100 at rest, on current
antihypertensive regimen

- Uncontrolled diabetes mellitus (hemoglobin A1C > 9%)

- Severe renal (estimated GFR < 30 ml/min) or hepatic disease/failure

- Severe anemia (Hgb < 9)

- Primary exercise limitation due to severe pulmonary disease

- Unacceptably poor echocardiographic images for analysis

- Worse than moderate mitral or aortic stenosis or insufficiency.

- Non-hypertensive cause of HFpEF (e.g. valvular disease, congenital heart disease,
amyloidosis, sarcoidosis, constrictive pericardial syndromes)

- Myocardial infarction or unstable angina, including new or worsening anginal
syndrome, within the past three months

- Uncontrolled arrhythmia (including non rate-controlled atrial fibrillation)

- Terminal illness expected to result in death within six months or active solid-organ
cancer

- Psychiatric disorder (or dementia) with potential to compromise adherence

- Changes in medical regimen for heart disease or hypertension within past 1 month
(except diuretic dose adjustment)
We found this trial at
1
site
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials